Skip to main content

 Scientific publications

Intravenous iron therapy for anemic cancer patients: a review of recently published clinical studies.

Authors : Lebrun F, Klastersky J, Levacq D, Wissam Y, Paesmans M
Year : 2017
Journal : Support Care Cancer
Volume : 25(7)
Pages : 2313-2319

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

Authors : Hortobagyi GN, Chen D, Piccart-Gebhart M, Rugo HS, Burris HA 3rd, Pritchard KI, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Masuda N, Dakhil S, Anderson I, Robinson DM, He W, Garg A, McDonald ER 3rd, Bitter H, Huang A, Taran T, Bachelot T, Lebrun F, Lebwohl D, Baselga J
Year : 2016
Journal : J Clin Oncol
Volume : 34(5)
Pages : 419-26

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.

Authors : Ignatiadis M, Zardavas D, Lemort M, Wilke C, Vanderbeeken MC, Dhondt V, de Azambuja E, Gombos A, Lebrun F, Dal Lago L, Bustin F, Maetens M, Ameye L, Veys I, Michiels S, Paesmans M, Larsimont D, Sotiriou C, Nogaret JM, Piccart-Gebhart M, Awada A
Year : 2016
Journal : PLoS ONE
Volume : 11(7)
Pages : e0154009

Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer.

Authors : Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I
Year : 2014
Journal : Oncologist
Volume : 19(4)
Pages : 348-9

Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer.

Authors : Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I
Year : 2014
Journal : Oncologist
Volume : 19(4)
Pages : 346-7

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†

Authors : Piccart-Gebhart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J
Year : 2014
Journal : Ann Oncol
Volume : 25(12)
Pages : 2357-62

Everolimus plus exemestane as first-line therapy in HR(+), HER2 (-) advanced breast cancer in BOLERO-2.

Authors : Beck JT, Hortobagyi GN, Campone M, Lebrun F, Deleu I, Rugo HS, Pistilli B, Masuda N, Hart L, Melichar B, Dakhil S, Geberth M, Nunzi M, Heng DY, Brechenmacher T, El-Hashimy M, Douma S, Ringeisen F, Piccart-Gebhart M
Year : 2014
Journal : Breast Cancer Res. Treat.
Volume : 143(3)
Pages : 459-67

Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.

Authors : de Azambuja E, Zardavas D, Lemort M, Rossari J, Moulin C, Buttice A, Dhondt V, Lebrun F, Lalami Y, Cardoso F, Sotiriou C, Gil T, Devriendt D, Paesmans M, Piccart-Gebhart M, Awada A
Year : 2013
Journal : Ann Oncol
Volume : 24(12)
Pages : 2985-9

Autoimmune haemolytic anaemia in a patient treated with capecitabine.

Authors : Sideris S, Loizidou A, Georgala A, Lebrun F, Gil T, Awada A, Piccart-Gebhart M, Cardoso F
Year : 2013
Journal : Acta Clin Belg
Volume : 68(2)
Pages : 135-7

Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.

Authors : Burris HA, Lebrun F, Rugo HS, Beck JT, Piccart-Gebhart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Ricci JF, Bauly H, Taran T, Sahmoud T, Noguchi S
Year : 2013
Journal : Cancer
Volume : 119(10)
Pages : 1908-15

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors : Baselga J, Campone M, Piccart-Gebhart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN
Year : 2012
Journal : N Engl J Med
Volume : 366(6)
Pages : 520-9

Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.

Authors : Awada A, Hendlisz A, Christensen O, Lathia CD, Bartholomeus S, Lebrun F, de Valeriola D, Brendel E, Radtke M, Delaunoit T, Piccart-Gebhart M, Gil T
Year : 2012
Journal : Eur. J. Cancer
Volume : 48(4)
Pages : 465-74